orforglipron + carbamazepine

**Orforglipron + carbamazepine** is a combination of two pharmaceutical agents used in research to assess the interaction between these drugs in healthy participants. Orforglipron is an oral small molecule glucagon-like peptide 1 receptor (GLP-1R) agonist developed for the treatment of obesity and type 2 diabetes. Carbamazepine is an oral anticonvulsant and mood-stabilizing drug that acts primarily as a sodium channel blocker. The mechanism of this combination study is to evaluate how carbamazepine induces hepatic enzymes (notably CYP3A4), potentially affecting orforglipron pharmacokinetics (absorption, metabolism, elimination) when co-administered. This combination is not a clinical therapy but is studied for pharmacokinetic and safety profiling in healthy volunteers[1][4][5][7].